Spiderwort Biotechnologies Inc. Announces State-of-the-Art ISO 5 Cleanroom Facility
New facility built exclusively by Spiderwort Biotechnologies Inc. will advance its mission to revolutionize regenerative medicine treatments
OTTAWA, CANADA — March 31, 2025 — Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced its state-of-the-art ISO 5 cleanroom facility at La Cité College in Ottawa, Canada. This milestone achievement marks a significant advancement in Spiderwort’s capabilities to accelerate the development and manufacturing of its Aerocell product technology.
The cleanroom, a controlled environment with minimal airborne particles, represents a critical step in the company’s journey from research to clinical applications. Designed specifically for the production of biomaterials suitable for human use, the facility enables Spiderwort Biotechnologies Inc. to manufacture biomaterials and medical devices under the stringent conditions required for regulatory approval and patient safety.
“This cleanroom facility represents a major achievement for us,” said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc. “It significantly enhances our manufacturing capabilities under the highest standards of quality and safety. As we continue to build on our platform technology, this investment underscores our commitment to transforming how we approach tissue engineering and biomaterials in medical contexts.”
The ISO 5 cleanroom features specialized design elements including:
- An air filtration system containing high-efficiency particulate absorbing filters (HEPA)
- Non-shedding, chemically resistant ceiling panels and walls.
- Positive air pressure to prevent external contamination, adhering to the rigorous standards necessary for medical device manufacturing.
Construction of the cleanroom began in December 2021 in collaboration with La Cité College, and achieved ISO 5 certification in August 2022, which has been maintained annually for continued compliance with international standards.
The cleanroom now serves Spiderwort Biotechnologies’ clinical roadmap in 2025, supporting development requirements of regulatory bodies in major markets. This capability is essential for advancing the company’s biotechnology platform through key regulatory milestones, accelerating the path from lab to in-human clinical testing.
“Our partnership with Spiderwort Biotechnologies represents our commitment to fostering meaningful industry partnerships and to offer a unique learning experience to our students,” said Nathalie Methot, Dean Academics and Research at La Cité. “This collaboration strengthens InnovaCité’s BIOlab position as a hub for biotechnology innovation and demonstrates how educational institutions play a vital role in supporting companies developing new medical technologies. We’re proud to be part of advancing research that will ultimately benefit patients and the broader healthcare, biotechnology, and entrepreneurship communities. “
“The cleanroom facility represents a significant advancement in the development of next-generation biomaterials,” said Dr. Gregory A. Buford, MD, FACS, PCEO. “What excites me most about Spiderwort’s approach is how they’re combining innovation with sustainability, creating advanced biomaterials that offer new possibilities for medical aesthetics outcomes.”
About Spiderwort Biotechnologies Inc.
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort’s biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.
Media Contact
Shannon Murphy
s.murphy@spiderwortbio.com
613-808-5939